Pfizer Stock Forecast for 2023 - 2025 - 2030
Updated on 05/30/2024
Pfizer Stock Forecast and Price Target
The average target price for Pfizer's stock set by six renowned analysts in recent months is $30.47, representing a potential upside of approximately 9.53% from its last closing price if met by 2025. This estimation is based on a high estimate of $45.00 and a low estimate of $27.00. If you are looking to invest in the stock, it's important to research and compare different companies.
9.53% Upside
Pfizer Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Pfizer's Price has decreased by 100.00%, going from $28.79 to $0.00. For the next year, analysts are expecting Fair Value to reach $58.49 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$811.53 | Buy/Sell | $636.99 | 8.13% |
| COST Stock Forecast | Costco Wholesale | Outperform |
11
|
$806.52 | Buy/Sell | $696.20 | -0.31% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$154.79 | Buy/Sell | $178.42 | 17.90% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£119.30 | Buy/Sell | £165.99 | 41.39% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$100.73 | Buy/Sell | $118.92 | 24.09% |
Pfizer Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer's Revenue has grown by 40.44%, from $41.65B to $58.50B. For the next year, analysts are expecting Revenue to reach $69.26B – an increase of 18.40%. By 2030, professionals predict that Pfizer's Revenue will decrease by 9.28%, to $53.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$296.37 | Buy/Sell | $303.65 | 8.75% |
| EL Stock Forecast | EssilorLuxottica Société ano... | Outperform |
12
|
203.20€ | Buy/Sell | 193.26€ | 1.38% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.20 | Buy/Sell | $205.51 | -26.15% |
.jpg)
Pfizer Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer's Dividend per Share has grown from $1.52 to $1.64 – a 7.89% increase. Next year, analysts are expecting Dividend per Share to reach $1.72 – an increase of 4.88%. Over the next seven years, the forecast is for Dividend per Share to grow by 3.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$40.25 | Buy/Sell | $58.15 | 34.16% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.45k | Buy/Sell | ¥5.24k | 13.72% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$225.07 | Buy/Sell | $284.47 | 24.41% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
10
|
$97.56 | Buy/Sell | $109.39 | 6.09% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥4.68k | Buy/Sell | ¥4.92k | 30.23% |
| BAS Stock Forecast | BASF | Outperform |
12
|
47.24€ | Buy/Sell | 49.50€ | 18.54% |
Pfizer EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer's EBITDA has decreased from $14.31B to $11.52B – a 19.54% drop! For next year, analysts predict EBITDA of $31.16B, which would mean an increase of 170.52%. Over the next seven years, experts predict that Pfizer's EBITDA will grow at a rate of 68.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$145.48 | Buy/Sell | $138.82 | 3.11% |
| BN Stock Forecast | Danone | Outperform |
11
|
58.52€ | Buy/Sell | 55.47€ | 9.36% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
143.60€ | Buy/Sell | 137.41€ | 3.76% |
Pfizer EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer has seen a decline in its EBIT, from $9.65B to $5.26B – a 45.50% decrease. In the next year, analysts believe that EBIT will reach $27.33B – an increase of 419.76%. For the next seven years, the forecast is for EBIT to grow by 309.29%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$214.41 | Buy/Sell | $299.62 | 34.56% |
| DSFIR Stock Forecast | DSM-Firmenich | Outperform |
18
|
105.30€ | Buy/Sell | 114.60€ | 14.91% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.93€ | Buy/Sell | 45.15€ | 13.26% |
Pfizer EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Pfizer's EPS has decreased by 100.00%, going from $2.22 to $0.00. For the next year, analysts are expecting EPS to reach $4.51 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr822.00 | Buy/Sell | kr812.28 | 9.49% |
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$103.31 | Buy/Sell | $96.90 | 4.54% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$93.23 | Buy/Sell | $123.75 | 0.34% |
.jpg)